We are a Biotech-startup focused on developing novel genetic therapies.
Our goal is to develop novel therapies that target only cells causing a disease, with minimal patient burden.
We create the future where our therapies allow patients to live healthier and more fulfilling lives.
We believe our ingenuity and curiosity can lead us to the future.
aceRNA Technology and Pfizer entered into an agreement to collaborate on RNA switch technology. In the collaboration, we aim to engineer RNA switch for potential targeted mRNA medicines.
As of May 26th, Teruo Susumu has resigned from his position as President and CEO at aceRNA Technologies. Fumihiro Sugawa will serve as the new President and CEO. We will continue to develop “smart gene therapy” (mRNA-based and virus-base) that enables control of therapeutic transgene expression in cell-type and -state specific manner.